Inhibition of GSK3β improves hippocampusdependent learning and rescues neurogenesis in a mouse model of fragile X syndrome

138Citations
Citations of this article
125Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Fragile X syndrome (FXS), a common inherited form of intellectual disability with learning deficits, results from a loss of fragile X mental retardation protein (FMRP). Despite extensive research, treatment options for FXS remain limited. Since FMRP is known to play an important role in adult hippocampal neurogenesis and hippocampus-dependent learning and FMRP regulates the adult neural stem cell fate through the translational regulation of glycogen synthase kinase 3β (GSK3β), we investigated the effects of a GSK3β inhibitor, SB216763, on Fmr1 knockout mice (Fmr1 KO). We found that the inhibition of GSK3β could reverse the hippocampus-dependent learning deficits and rescue adult hippocampal neurogenesis at multiple stages in Fmr1 KO mice. Our results point to GSK3β inhibition as a potential treatment for the learning deficits seen in FXS. © The Author 2011. Published by Oxford University Press. All rights reserved.

Cite

CITATION STYLE

APA

Guo, W., Murthy, A. C., Zhang, L., Johnson, E. B., Schaller, E. G., Allan, A. M., & Zhao, X. (2012). Inhibition of GSK3β improves hippocampusdependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Human Molecular Genetics, 21(3), 681–691. https://doi.org/10.1093/hmg/ddr501

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free